Barclays analyst Matt Miksic reiterated a Buy rating on Edwards Lifesciences (EW – Research Report) yesterday and set a price target of $100.00. The company’s shares closed yesterday at $86.61.
Miksic covers the Healthcare sector, focusing on stocks such as InMode, Becton Dickinson, and Edwards Lifesciences. According to TipRanks, Miksic has an average return of 6.6% and a 61.88% success rate on recommended stocks.
In addition to Barclays, Edwards Lifesciences also received a Buy from TD Cowen’s Josh Jennings in a report issued yesterday. However, on the same day, Canaccord Genuity maintained a Hold rating on Edwards Lifesciences (NYSE: EW).
See the top stocks recommended by analysts >>
Based on Edwards Lifesciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.48 billion and a net profit of $384.9 million. In comparison, last year the company earned a revenue of $1.32 billion and had a net profit of $343.5 million
Based on the recent corporate insider activity of 111 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EW in relation to earlier this year. Most recently, in December 2023, Daveen Chopra, the CVP, TMTT of EW sold 7,000.00 shares for a total of $547,680.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Edwards Lifesciences (EW) Company Description:
Incorporated in 1958, California-based Edwards Lifesciences Corp. is a medical technology company, which specializes in structural heart disease and critical care and surgical monitoring. It reports in three segments: Transcatheter Aortic Valve Replacements, Transcatheter Mitral and Tricuspid Therapies and Surgical Structural Heart and Critical Care.
Read More on EW:
- Edwards Lifesciences sees Q1 adjusted EPS 62c-66c, consensus 66c
- Edwards Lifesciences sees Q1 adjusted EPS 62c-66c, consensus
- Edwards Lifesciences backs FY24 adjusted EPS $2.70-$2.80, consensus $2.76
- Edwards Lifesciences reports Q4 adjusted EPS 64c, consensus 64c
- Edwards Lifesciences options imply 5.5% move in share price post-earnings
